You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
1 June 2026 - Biopharmaceutical company Avacta Group PLC (AIM: AVCT) announced on Monday that it has presented updated clinical data from its Phase 1a/1b trial of AVA6000, its pre|CISION-enabled form of doxorubicin, highlighting encouraging early eff...
1 June 2026 - Chinese biopharmaceutical company Dizal (SSE:688192) announced on Saturday the presentation of two studies in non-small cell lung cancer (NSCLC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.One study evaluated...
1 June 2026 - TiumBio Co Ltd (KOSDAQ:321550), a South Korea-based clinical-stage biopharmaceutical company, on Sunday announced clinical data for Tosposertib (TU2218), an oral dual inhibitor targeting transforming growth factor-beta (TGF-beta) and va...
1 June 2026 - Chinese biopharmaceutical company ImmVira Group announced on Sunday that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was presented at the 2026 American Society of Clinical Oncology (ASC...
1 June 2026 - CARsgen Therapeutics Holdings Limited (HK:2171), a Chinese developer of innovative CAR T-cell therapies, announced on Monday that the long-term analysis results of satricabtagene autoleucel (satri-cel, CT041) (an autologous CAR T-cell p...
29 May 2026 - South Korean biopharmaceutical company Samsung Bioepis Co Ltd announced on Friday the launch of OPUVIZ (aflibercept) 40 mg/mL solution for injection in a vial across Europe.OPUVIZ, an aflibercept biosimilar referencing Regeneron Pharmac...